Skip to main content
IRS-authorized e-file provider · not the IRS

Nonprofit · EIN 93-2407167

INTERNATIONAL BLADDER CANCER GROUP

Tax-exempt · FLEMINGTON, NJ 08822

Financials

$392K$311K2024$603K$437K2025
Revenue Expenses · by fiscal year end
Financials of INTERNATIONAL BLADDER CANCER GROUP by year, from its e-filed returns
Year endedFormRevenueExpensesNet incomeTotal assetsLiabilitiesNet assets
December 31, 2025990$603,104$436,909$166,195$248,123$347$247,776
December 31, 2024990$392,488$310,907$81,581$97,433$15,852$81,581
Financial details: 990 for the year ended December 31, 2025

Revenue

Contributions, gifts and grants
$603,026
Program service revenue
$0
Investment income
$78
Other revenue
$0

Expenses

Grants and similar amounts paid
$0
Compensation of officers, directors and key employees
$0
Salaries, compensation and benefits (total)
$0
Professional fundraising fees
$0
Program services (functional)
$429,066
Management and general (functional)
$7,843

Balance sheet and other

Total assets, start of year
$97,433
Total assets, end of year
$248,123
Total liabilities, end of year
$347
Net assets, end of year
$247,776
Net assets without donor restrictions
$247,776
Gross receipts
$603,104
Employees
0
Year formed
2023
State of legal domicile
TX

From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.

Officers, directors and key employees

As listed on the 990 for the year ended December 31, 2025, highest compensation first.

NameTitleHours / weekCompensation
Ashish Kamat MDPresident
Trustee or director
3.5$0
Roger Buckley MDVice President
Trustee or director
1$0
Prem Kumar ParameswaranTreasurer
Trustee or director
6.5$0
990 for the year ended December 31, 2024: 3 people
NameTitleHours / weekCompensation
Ashish Kamat MDPresident
Trustee or director
3.5$0
Roger Buckley MDVice President
Trustee or director
1$0
Prem Kumar ParameswaranTreasurer
Trustee or director
6.5$0

Address and contacts

Address (IRS master file)
12 WINDHAM CT, FLEMINGTON, NJ 08822-3505
Signed the 990
Prem Kumar Parameswaran, Treasurer
Phone
(516) 359-6257
Return prepared by
Kornfeld and Associates CPAs

Mission

The International Bladder Cancer Group (IBCG) is a globally recognized entity that has published numerous peer-reviewed articles addressing knowledge gaps in - and providing recommendations for - the management of bladder cancer.The IBCG was formed with a primary objective being to address global educational needs and learning gaps in order to improve the care and management of patients with urothelial carcinoma. The inaugural meeting, in 2006, consisted of members selected as representatives of their varied geographic regions across Europe, North America and Asia. The members were specifically selected not only for their expertise but also to ensure representation from across the globe.Over the years, the mission of the IBCG has been to improve outcomes of patients suffering from bladder cancer through critical evaluation and leveraging of existing data to drive evidence-based treatment. An additional goal is to develop practical educational tools that are applicable to the global uro

990 for the year ended December 31, 2025

Program accomplishments

  • The IBCG has expanded its membership in the past few years to include many globally recognized experts in the field of bladder cancer. This expansion has included a wide range of health care professionals including medical oncologists, radiation oncologists, statisticians and researchers with representation to include all the continents. In 2021, the IBCG created a Health Services Research group led by Dr. Stephen B Williams which aims to be the collaborative source for clinicians and researchers. An IBCG newsletter under Chief Editor Dr. Fred Witjes was launched in Q1 2022. In August 2025, the IBCG held a retreat (#IBCG25) to discuss 2 very important topics: Biomarkers in Urothelial CancerToxicity of Local Therapies for Bladder CancerThis retreat led by our program chairs, Drs. Shilpa Gupta, Roger Li, and Patrick Hensley opened its doors to a wider audience with partners from industry invited to join the KOLs and patient advocates, and resulted in robust discussions directed towards improving care for our patients. Other activities include: AUA - IBCG Bladder Cancer Forum - held in 2022 ,2023, 2024 and 2025; IBCG collaboration with Mexican Urological Society to develop Mexican Bladder Cancer Guidelines; Collaborative effort between GSRGT and IBCG to tackle variant histology/histologic subtypes in bladder cancer. The IBCG will continue to support ongoing initiatives including clinical trial design, clinical research, national and international guideline assistance, and conference or symposium organization.
    Expenses $429,066 · revenue $603,026

What it must file and when

IRS records say it files Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N. Its accounting year ends in December, so each return is due on the 15th day of the 5th month after that.

Tax yearYear endedDueIRS public records
2025December 31, 2025May 15, 2026990 on file
2024December 31, 2024May 15, 2025990 on file
2023December 31, 2023May 15, 2024Check at the IRS

IRS record

EIN
93-2407167
Tax-exempt status
501(c)(3): Charitable, religious, educational or scientific organization
Foundation status
Publicly supported organization (170(b)(1)(A)(vi))
Donations deductible (Pub 78)
Public charity, 50% deduction limit
Exempt since
2024
Accounting year ends
December
Files
Form 990 or 990-EZ
Category (NTEE)
Medical research (H03)
Assets (IRS master file)
$248,123
Income (IRS master file)
$603,104

Filing history

FormYear endedRevenueExpensesAssetsReturn
990December 2025$603,104$436,909$248,123IRS
990December 2024$392,488$310,907$97,433XML

990-N: the IRS bulk file holds only the latest e-Postcard per organization; earlier years come from archived copies of that file since 2020 and can have gaps (the IRS e-Postcard search lists every one). 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS (search EIN 93-2407167).

Questions about INTERNATIONAL BLADDER CANCER GROUP

What is the EIN of INTERNATIONAL BLADDER CANCER GROUP?
The employer identification number (EIN) of INTERNATIONAL BLADDER CANCER GROUP is 93-2407167.
Is INTERNATIONAL BLADDER CANCER GROUP tax-exempt?
Yes. The IRS lists it as tax-exempt under section 501(c)(3) since 2024.
Are donations to INTERNATIONAL BLADDER CANCER GROUP tax-deductible?
Yes. It is listed in IRS Publication 78 (Public charity, 50% deduction limit).
Which annual return does INTERNATIONAL BLADDER CANCER GROUP file?
Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N.
When is the next return of INTERNATIONAL BLADDER CANCER GROUP due?
The return for tax year 2026 (the year ending December 31, 2026) is due May 17, 2027. Form 8868 extends it by six months; the 990-N cannot be extended.
When did INTERNATIONAL BLADDER CANCER GROUP last file with the IRS?
The latest return in the IRS public files is the 990 for the year ended December 2025.
Who are the officers and directors of INTERNATIONAL BLADDER CANCER GROUP?
The 990 for the year ended December 31, 2025 lists 3 people; 0 received compensation from the organization.
How much revenue does INTERNATIONAL BLADDER CANCER GROUP have?
On its 990 for the year ended December 31, 2025 it reported revenue of $603,104, expenses of $436,909 and total assets of $248,123 at year end.

Other nonprofits in FLEMINGTON

All nonprofits in FLEMINGTON · New Jersey · Medical research